ArticleThe Lancet. Rheumatology2023
Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.
Article in The Lancet. Rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 235 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
235 citing papers in PubMed, 9 syntheses or guidelines pooled it, 329 citations in OpenAlex.
- Effects of Digital Health Interventions in Chronic Musculoskeletal Pain: Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials.Journal of medical Internet research · 2026Pooled it
- A systematic review and meta-analysis on the epidemiology of work-related musculoskeletal disorders among nurses in Ethiopia.PloS one · 2026Pooled it
- Connectomic Mapping of Chronic Musculoskeletal Pain: Neural Circuitries Identified Through a Systematic Review and ALE Meta-Analysis.Neural plasticity · 2026Pooled it
- Prevalence of vasculitis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies and spondyloarthritis in Australia: a systematic review and meta-analysis.Internal medicine journal · 2025Pooled it
- Optimising postoperative spine outcomes: an umbrella review of enhanced recovery after spinal surgery (ERASS) protocols.British journal of anaesthesia · 2025Pooled it
- Pooled it
- Effects of acupuncture on musculoskeletal pain: an evidence map.Frontiers in medicine · 2025Pooled it
- Efficacy of telerehabilitation for total knee arthroplasty: a meta-analysis based on randomized controlled trials combined with a bibliometric study.Journal of orthopaedic surgery and research · 2024Pooled it
- Effectiveness of Physical Activity in the Management of Nonspecific Low Back Pain: A Systematic Review.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Influence of a passive shoulder exoskeleton on drilling performance in women- a cross-sectional study.Scientific reports · 2026Trial
- Trial
- Trial
- Effectiveness of a dynamic seat cushion on recovery and recurrence of neck and low back pain in office workers: a secondary analysis of a randomized controlled trial.BMC musculoskeletal disorders · 2024Trial
- Efficacy of prehabilitation modalities in total knee arthroplasty:Osteoarthritis and cartilage open · 2026Review
- Exercise modality and subsequent musculoskeletal medical expenditures among middle-aged and older adults: A population-based longitudinal study.Journal of exercise science and fitness · 2026Article
- Rapid adaptation of first contact physiotherapy services for musculoskeletal patients in the UK and Australia during the COVID-19 pandemic: A multiple case study.Journal of health services research & policy · 2026Article
- Versatile Microgel Platform for Intervertebral Disc Degeneration Therapy: Targeting Pericyte-Mediated Fibrosis and Protecting Nucleus Pulposus Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ammonia Accumulation Drives Intervertebral Disc Degeneration by Triggering Ammonia-Induced Cell Death Through Lysosome-Mitochondria Crosstalk.Cell proliferation · 2026Article
- Article
- Restoring pre-osteoarthritis cartilage matrix integrity via Col9 mRNA halts osteoarthritis progression.Science advances · 2026Article
175 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Musculoskeletal disorders include more than 150 different conditions affecting joints, muscles, bones, ligaments, tendons, and the spine. To capture all health loss from death and disability due to musculoskeletal disorders, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) includes a residual musculoskeletal category for conditions other than osteoarthritis, rheumatoid arthritis, gout, low back pain, and neck pain. This category is called other musculoskeletal disorders and includes, for example, systemic lupus erythematosus and spondylopathies. We provide updated estimates of the prevalence, mortality, and disability attributable to other musculoskeletal disorders and forecasted prevalence to 2050. Methods: Prevalence of other musculoskeletal disorders was estimated in 204 countries and territories from 1990 to 2020 using data from 68 sources across 23 countries from which subtraction of cases of rheumatoid arthritis, osteoarthritis, low back pain, neck pain, and gout from the total number of cases of musculoskeletal disorders was possible. Data were analysed with Bayesian meta-regression models to estimate prevalence by year, age, sex, and location. Years lived with disability (YLDs) were estimated from prevalence and disability weights. Mortality attributed to other musculoskeletal disorders was estimated using vital registration data. Prevalence was forecast to 2050 by regressing prevalence estimates from 1990 to 2020 with Socio-demographic Index as a predictor, then multiplying by population forecasts. Findings: Globally, 494 million (95% uncertainty interval 431-564) people had other musculoskeletal disorders in 2020, an increase of 123·4% (116·9-129·3) in total cases from 221 million (192-253) in 1990. Cases of other musculoskeletal disorders are projected to increase by 115% (107-124) from 2020 to 2050, to an estimated 1060 million (95% UI 964-1170) prevalent cases in 2050; most regions were projected to have at least a 50% increase in cases between 2020 and 2050. The global age-standardised prevalence of other musculoskeletal disorders was 47·4% (44·9-49·4) higher in females than in males and increased with age to a peak at 65-69 years in male and female sexes. In 2020, other musculoskeletal disorders was the sixth ranked cause of YLDs globally (42·7 million [29·4-60·0]) and was associated with 83 100 deaths (73 600-91 600). Interpretation: Other musculoskeletal disorders were responsible for a large number of global YLDs in 2020. Until individual conditions and risk factors are more explicitly quantified, policy responses to this burden remain a challenge. Temporal trends and geographical differences in estimates of non-fatal disease burden should not be overinterpreted as they are based on sparse, low-quality data. Funding: Bill & Melinda Gates Foundation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.